Press Kythera Biopharmaceuticals Inc. Published: 17 March 11 Kythera Biopharmaceuticals, Inc. (Kythera) today reported additional efficacy data a third phase II clinical study ATX-101, an agent adipolytic, first in his class that is being investigated by the reduction of submental (â € ~ in China € ™) of fat. TIG welding stainless steel corner joints filler wire